CTOR CITIUS ONCOLOGY, INC.

Nasdaq www.citiusonc.com/overview/default.aspx


$ 1.57 $ -0.08 (-4.85 %)    

Wednesday, 05-Nov-2025 12:58:04 EST
QQQ $ 625.00 $ 6.51 (1.05 %)
DIA $ 473.97 $ 3.10 (0.66 %)
SPY $ 680.33 $ 5.29 (0.78 %)
TLT $ 89.04 $ -0.47 (-0.52 %)
GLD $ 366.27 $ -0.15 (-0.04 %)
$ 1.57
$ 1.56
$ 1.57 x 100
$ 1.59 x 114
$ 1.56 - $ 1.57
$ 0.55 - $ 6.19
94,584
na
112.34M
$ -0.97
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 02-14-2025 12-31-2024 10-Q
4 12-27-2024 09-30-2024 10-K
5 08-09-2024 06-30-2024 10-Q
6 05-20-2024 03-31-2024 10-Q
7 04-16-2024 12-31-2023 10-K
8 11-20-2023 09-30-2023 10-Q
9 08-16-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 04-17-2023 12-31-2022 10-K
12 11-28-2022 09-30-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

McKesson joins leading distribution service providers as authorized U.S. distributor of LYMPHIRCRANFORD, N.J., Oct. 20, 2025 /P...

Core News & Articles

EVERSANA to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated Cutan...

Core News & Articles

Exclusive relationship through Named Patient Programs establishes footprint in Greece, Cyprus and additional Balkan countriesCR...

Core News & Articles

Maxim Group analyst Michael Okunewitch upgrades Citius Oncology (NASDAQ:CTOR) from Hold to Buy and announces $6 price target.

Core News & Articles

Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc...

Core News & Articles

Proprietary model informs targeted sales and marketing strategies with feedback loop thataugments precision and impact of targe...

Core News & Articles

Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.1...

Core News & Articles

Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), a majority-owned subsidiary of Citius...

Core News & Articles

Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for ...

Core News & Articles

-SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION